Androgen Deprivation Therapy increase the thromboembolic risk in patients treated for prostate cancer

18.07.2018

Androgen deprivation therapy (ADT) for prostate cancer can increase the risk of thromboembolic events, according to a recent systematic review and meta-analysis.

Compared with no ADT, treatment with gonadotropin-releasing hormone (GnRH) agonists alone, GnRH agonists plus oral anti-androgens (AA), and AA alone is associated with a significant 1.47-, 2.55- and 1.49-fold increased risk of deep vein thrombosis (DVT), respectively. However, DVT was not significantly associated with orchiectomy.

In addition, use of GnRH agonists alone and orchiectomy were associated with a significant 2.26- and 2.12-fold increased risk of pulmonary embolism, respectively.

These findings may contribute to the clinician's awareness regarding the potential risk of ADT and ensure clinical management when prescribing this treatment.

Reference

Guo Z, Huang Y, Gong L, et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2018; published online ahead of print.